114 related articles for article (PubMed ID: 34489355)
21. Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
Plotti F; Capriglione S; Terranova C; Montera R; Aloisi A; Damiani P; Muzii L; Scaletta G; Benedetti-Panici P; Angioli R
Tumour Biol; 2012 Dec; 33(6):2117-23. PubMed ID: 22875782
[TBL] [Abstract][Full Text] [Related]
22. Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer.
Rosendahl M; Harter P; Bjørn SF; Høgdall C
Int J Gynecol Cancer; 2018 Feb; 28(2):316-322. PubMed ID: 29324538
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
24. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer.
Prayer L; Kainz C; Kramer J; Stiglbauer R; Schurawitzki H; Baldt M; Schima W; Poelzleitner D; Reinthaller A; Koelbl H
J Comput Assist Tomogr; 1993; 17(4):626-32. PubMed ID: 8331235
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
Campbell R; King MT; Ross TL; Cohen PA; Friedlander ML; Webb PM
Gynecol Oncol; 2021 Nov; 163(2):398-407. PubMed ID: 34481610
[TBL] [Abstract][Full Text] [Related]
26. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
27. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bendifallah S; Body G; Daraï E; Ouldamer L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
[TBL] [Abstract][Full Text] [Related]
28. Development of a preoperative computed tomography score for the management of advanced epithelial ovarian cancer.
Fuso L; Ferrero A; Vietti E; Petracchini M; Mineccia M; Villa M; Menato G
Int J Gynecol Cancer; 2019 Mar; 29(3):599-604. PubMed ID: 30829578
[TBL] [Abstract][Full Text] [Related]
29. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
King MT; Stockler MR; O'Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML;
Qual Life Res; 2018 Jan; 27(1):59-74. PubMed ID: 29248998
[TBL] [Abstract][Full Text] [Related]
30. The Use of Platelet/Lymphocyte Ratio and Cancer Antigen 125 Combined with Magnetic Resonance Diffusion-Weighted Imaging in Diagnosis of Recurrent Ovarian Cancer and Neuropathic Pain.
Wang N; Li C; Yang Y; Guan Y; Wang F; Wang Y; Zhao W
World Neurosurg; 2021 May; 149():502-510. PubMed ID: 33326856
[TBL] [Abstract][Full Text] [Related]
31. Have Volume-based Parameters of Positron Emission Tomography/Computed Tomography Prognostic Relevance for Patients With Potentially Platinum-responsive Recurrent Ovarian Cancer? A Single Center Italian Study.
Gadducci A; Simonetti E; Guidoccio F; Manca G; Giorgetti A; Depalo T; Cosio S; Miccoli M; Volterrani D
Anticancer Res; 2021 Apr; 41(4):1937-1944. PubMed ID: 33813399
[TBL] [Abstract][Full Text] [Related]
32. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
33. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
34. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.
Lutgendorf SK; Shinn E; Carter J; Leighton S; Baggerly K; Guindani M; Fellman B; Matzo M; Slavich GM; Goodman MT; Tew W; Lester J; Moore KM; Karlan BY; Levine DA; Sood AK
Gynecol Oncol; 2017 Jul; 146(1):101-108. PubMed ID: 28527672
[TBL] [Abstract][Full Text] [Related]
35. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.
Friedlander M; Rau J; Lee CK; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Hilpert F; King MT; Debruyne P; Bologna A; Malander S; Monk BJ; Petru E; Calvert P; Herzog TJ; Barrett C; du Bois A
Ann Oncol; 2018 Mar; 29(3):737-743. PubMed ID: 29267856
[TBL] [Abstract][Full Text] [Related]
36. Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?
El Bairi K; Afqir S; Amrani M
Curr Drug Targets; 2020; 21(10):1026-1033. PubMed ID: 32334501
[TBL] [Abstract][Full Text] [Related]
37. Acceptability and Feasibility of Early Palliative Care Among Women with Advanced Epithelial Ovarian Cancer: A Randomized Controlled Pilot Study.
Cusimano MC; Sajewycz K; Harle I; Giroux J; Hanna T; Willing S; Martin V; Francis JA
J Obstet Gynaecol Can; 2021 Jun; 43(6):707-715. PubMed ID: 33731311
[TBL] [Abstract][Full Text] [Related]
38. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
[TBL] [Abstract][Full Text] [Related]
39. Development and Validation of a Predictive Score for Preoperative Diagnosis of Early Stage Epithelial Ovarian Cancer.
Chirdchim W; Wanichsetakul P; Phinyo P; Patumanond J; Suwannarurk K; Srisomboon J
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1207-1213. PubMed ID: 31030496
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]